✦ LIBER ✦

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

✍ Scribed by Jian-Feng Lu; Rene Bruno; Steve Eppler; William Novotny; Bert Lum; Jacques Gaudreault

Publisher: Springer
Year: 2008
Tongue: English
Weight: 389 KB
Volume: 62
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-007-0664-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetic analysis of irinotecan p

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors

✍ Crystal S. Denlinger; Rebecca Blanchard; Lu Xu; Coen Bernaards; Samuel Litwin; C 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 386 KB

Clinical pharmacokinetics of intravenous

Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors

✍ Ralf Axel Hilger; Andreas Harstrick; Wilfried Eberhardt; Carsten Oberhoff; Matth 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 302 KB

Pharmacokinetics of 7-con-O-methylnogaro

Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors

✍ M. L. Zanette; U. Tirelli; R. Sorio; D. Zadro; F. Figoli; S. Monfardini; M. D'In 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 323 KB

Phase I study of cetuximab, erlotinib, a

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

✍ Chia-Chi Lin; Emiliano Calvo; Kyriakos P. Papadopoulos; Amita Patnaik; John Sara 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 278 KB

Safety and pharmacokinetics of panitumum

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors

✍ Toshihiko Doi; Atsushi Ohtsu; Makoto Tahara; Tomohide Tamura; Kuniaki Shirao; Ya 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 284 KB

Phase I clinical trial and pharmacokinet

Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors

✍ Charles L. Vogel; Elizabeth Gorowski; Enrique Davila; Mario Eisenberger; James K 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 823 KB

ICRF-187 was given to 62 evaluable patients with advanced solid tumors in a Phase I clinical trial. Weekly infusions were given in dosages ranging from 0.85 g/m2 to 7.42 g/m2 for a total of four weeks with a two week rest period between courses. Dose-limiting hematological toxicity was seen in heavi